Recent discussions on X about Pfizer Inc. (PFE) have been ignited by the company's landmark agreement with the U.S. government to slash drug prices by up to 85%, alongside positive trial data for a weight-loss drug. Many users are highlighting the stock's significant intraday jump of over 7% as a sign of market approval, while others are debating the long-term implications of this pricing strategy on profitability. The conversation reflects a mix of optimism and caution as investors weigh the benefits against potential regulatory challenges.
Additionally, posts on X have pointed to analyst commentary, with some viewing the deal as a positive catalyst for the pharmaceutical sector, while others remain skeptical about its broader impact. There's also chatter about Pfizer's reaffirmed commitment to vaccine safety and global health initiatives, which has sparked varied reactions among users. This development, paired with the stock's recent performance, continues to keep Pfizer at the forefront of investor discussions.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Inc. Congressional Stock Trading
Members of Congress have traded $PFE stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/30, 04/29 and 1 sale worth up to $15,000 on 08/05.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 07/16 and 1 sale worth up to $15,000 on 08/04.
- SENATOR RON WYDEN sold up to $15,000 on 06/03.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 06/03.
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 2 times. They made 1 purchase worth up to $50,000 on 05/15 and 1 sale worth up to $50,000 on 04/08.
- REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Pfizer Inc. Hedge Fund Activity
We have seen 1,246 institutional investors add shares of Pfizer Inc. stock to their portfolio, and 1,454 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 26,490,160 shares (-25.6%) from their portfolio in Q2 2025, for an estimated $642,121,478
- BLACKROCK, INC. added 20,709,704 shares (+4.4%) to their portfolio in Q2 2025, for an estimated $502,003,224
- AMUNDI removed 14,642,887 shares (-28.1%) from their portfolio in Q2 2025, for an estimated $354,943,580
- MARSHALL WACE, LLP removed 13,641,127 shares (-96.8%) from their portfolio in Q2 2025, for an estimated $330,660,918
- CAPITAL WORLD INVESTORS removed 13,368,274 shares (-49.1%) from their portfolio in Q2 2025, for an estimated $324,046,961
- QUBE RESEARCH & TECHNOLOGIES LTD removed 10,711,578 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $259,648,650
- VICTORY CAPITAL MANAGEMENT INC added 10,400,851 shares (+220.6%) to their portfolio in Q2 2025, for an estimated $252,116,628
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pfizer Inc. Government Contracts
We have seen $1,715,709 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STERILE WATER FOR INJECTION 20ML: $1,167,976
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4567359319!NALOXONE 4 MG/10 ML VIAL 10ML: $59,220
- 4568572944!NALOXONE 4 MG/10 ML VIAL 10ML: $11,280
- 4568676827!HEXTEND 6%-LACT ELEC BAG 500ML: $11,164
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Pfizer Inc. Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 6 analysts offer price targets for $PFE in the last 6 months, with a median target of $25.5.
Here are some recent targets:
- Tim Anderson from B of A Securities set a target price of $28.0 on 08/06/2025
- Terence Flynn from Morgan Stanley set a target price of $33.0 on 08/06/2025
- Andrew Baum from Citigroup set a target price of $26.0 on 08/06/2025
- Trung Huynh from UBS set a target price of $25.0 on 04/30/2025
- Carter Gould from Cantor Fitzgerald set a target price of $24.0 on 04/22/2025
- Asad Haider from Goldman Sachs set a target price of $25.0 on 04/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
